How PSI-IBD benefits to society
IBD is one of the immune mediated inflammatory diseases (IMID) that is showing a rising incidence worldwide. Therefore, exploration of (modifiable) factors involved in disease development as well as its course is crucial for future preventative strategies. Also, research focused on prediction of medication efficacy instead of the current trial-and-error treatment strategy, will potentially lead to better disease management (i.e. shorter time to remission) and decrease in health care costs.